Niagen Bioscience, Inc.
NAGE
$6.76
$0.223.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.18M | 1.88M | -15.00K | -492.00K | 114.00K |
| Total Depreciation and Amortization | 358.00K | 366.00K | 370.00K | 390.00K | 373.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.07M | 748.00K | 1.22M | 1.04M | 1.07M |
| Change in Net Operating Assets | 5.11M | 503.00K | -1.84M | -643.00K | -912.00K |
| Cash from Operations | 8.58M | 3.50M | -264.00K | 295.00K | 649.00K |
| Capital Expenditure | -69.00K | -41.00K | -12.00K | -41.00K | -21.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 20.00K | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -69.00K | -21.00K | -12.00K | -41.00K | -21.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.00K | -4.00K | -2.00K | -3.00K | -1.00K |
| Issuance of Common Stock | 3.79M | 1.04M | 598.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -41.00K | 0.00 | 0.00 | -11.00K | -75.00K |
| Cash from Financing | 3.75M | 1.04M | 596.00K | -14.00K | -76.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.26M | 4.51M | 320.00K | 240.00K | 552.00K |